Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23832652 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL16446872 | 0.82 | HPGD (0.57) | RAB9AHPGDALDH1A1LMNATSHR | |
| SCHEMBL31601657 | 0.82 | ALDH1A1 (0.62) | SMN1; SMN2HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL15453396 | 0.78 | ALDH1A1 (0.81) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL31560091 | 0.75 | ALDH1A1 (0.57) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL10956804 | 0.75 | MAPK1 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL22849443 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL5523975 | 0.74 | ALDH1A1 (0.75) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL1300404 | 0.73 | BRD4 (0.45) | LMNACYP1A2CYP2D6TSHR | |
| SCHEMBL1300406 | 0.73 | BRD4 (0.45) | LMNACYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4712974-A2 | STAT DEGRADERS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709370-A2 | STAT DEGRADERS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4665332-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4665456-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | Arvinas Operations, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2021127283-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127283-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264490-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | SMN1; SMN2 1781/4885NPC1 2384/4885RAB9A 4491/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | SMN1; SMN2 2865/4885NPC1 1390/4885RAB9A 3935/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | SMN1; SMN2 737/4885NPC1 1158/4885RAB9A 2206/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | SMN1; SMN2 960/4885NPC1 1765/4885RAB9A 4525/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | SMN1; SMN2 3627/4885NPC1 2896/4885RAB9A 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.